Evidence map›Paper›PMID 25368528›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2014

Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations.

Abdullatif Taha Babakr, Osman Mohamed Elsheikh, Abdullah A Almarzouki, Adel Mohamed Assiri, Badr Eldin Elsonni Abdalla, Hani Yousif Zaki, Samir H Fatani, EssamEldin Mohamed NourEldin

Open access · goldAbstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Roles of antibody against oxygenized low density lipoprotein in atherosclerosis: recent advances.International journal of clinical and experimental medicine · 2015
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Abdullatif Taha BabakrDepartment of Medical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Osman Mohamed ElsheikhDepartment of Biochemistry, Faculty of Medicine, International University of Africa, Khartoum, Sudan.
Abdullah A AlmarzoukiDepartment of Internal Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Adel Mohamed AssiriDepartment of Medical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Badr Eldin Elsonni AbdallaDepartment of Biochemistry, Sciences Faculty for Girls, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Hani Yousif ZakiDepartment of Biochemistry and Nutrition, Faculty of Medicine, University of Gezira, Sudan.
Samir H FataniDepartment of Medical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
EssamEldin Mohamed NourEldinDepartment of Medical Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Umm al-Qura University · SAInternational University of Africa · SDKing Abdulaziz University · SAUniversity of Gezira · SD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutoantibodies to oxidized low-density lipoprotein (oxLDL) are a heterogeneous group of antibodies that are controversially discussed to be either pathogenic or protective. Biochemical and anthropometric measurements correlated with increased levels of these antibodies are also controversial, especially in conditions of impaired glucose tolerance and type 2 diabetes mellitus. The present study was conducted to evaluate levels of oxLDL antibodies and their correlation with obesity in different glycemic situations.

methodsTwo hundred and seventy-four adult males were classified into three subgroups: group 1 (n=125), comprising a control group of nondiabetic subjects; group 2 (n=77), comprising subjects with impaired glucose tolerance; and group 3 (n=72), comprising patients with type 2 diabetes mellitus. Body mass index was calculated, and measurement of oxLDL and oxLDL antibodies was performed.

resultsHigher mean concentrations of oxLDL were found in the type 2 diabetes mellitus and impaired glucose tolerance groups (143.5±21.9 U/L and 108.7±23.7 U/L, respectively). The mean value for the control group was 73.5±27.5 U/L (P<0.001). Higher mean concentrations of anti-oxLDL antibodies were observed in the type 2 diabetes mellitus and impaired glucose tolerance groups (55.7±17.8 U/L and 40.4±17.6 U/L, respectively). The mean value for the control group was 20.4±10 U/L (P<0.001). Levels of anti-oxLDL antibodies were found to be positively and significantly correlated with body mass index in the control group (r=0.46), impaired glucose tolerance (r=0.51), type 2 diabetes mellitus group (r=0.46), and in the whole study population (r=0.44; P<0.001).

conclusionAnti-oxLDL antibody levels were increased in subjects with type 2 diabetes mellitus and impaired glucose tolerance and were positively correlated with obesity and body mass index.

Indexed as

anti-oxidized low-density lipoprotein antibodiesbody mass indexdiabetesimpaired glucose toleranceobesity

Identifiers

PMID25368528
PMCPMC4216034
OpenAlexW2069515174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.